CSL Ltd. - ADR
CSLLY
Market Cap$154.73B
Close$
Earnings Call Q4 2023
August 15, 2023 - AI Summary
CSL delivered strong full-year results, with revenue up 31% at constant currency and NPATA of $2.6 billion, up 20%.
The CSL Behring business saw strong growth in its Ig franchise, with sales up 21%. Plasma collections reached record levels, and the company dosed its first patients with HEMGENIX, a gene therapy for hemophilia B.
CSL Seqirus achieved strong sales growth, driven by FLUCELVAX, which was up 30%. The company also signed a licensing agreement with Arcturus Therapeutics for next-generation mRNA vaccine technology.
Exclusive for Stockcircle Pro members
Sign up
$13.84
82.5% downside
Current Fair Value
82.5% downsideOvervalued by 82.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $154.73 Billion |
|---|---|
| Enterprise Value | $165.17 Billion |
| Dividend Yield | $1.325 (1.71961213004575%) |
| Earnings per Share | $1.37 |
| Beta | 0.33 |
| Outstanding Shares | 1,935,519,348 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 27.88 |
|---|---|
| PEG | 499.94 |
| Price to Sales | 5.26 |
| Price to Book Ratio | 7.9 |
| Enterprise Value to Revenue | 5.67 |
| Enterprise Value to EBIT | 19.47 |
| Enterprise Value to Net Income | 26 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About CSL Ltd.
CEO: Paul Perreault